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Abstract  
Sex hormones and their receptors play critical roles in the development and progression 
of the breast and prostate cancers. Here we report that a novel type of tRNA-derived small RNA, 
termed Sex HOrmone-dependent TRNA-derived RNAs (SHOT-RNAs), are specifically and 
abundantly expressed in estrogen receptor (ER)-positive breast cancer and androgen receptor 
(AR)-positive prostate cancer cell lines. SHOT-RNAs are not abundantly present in ER-
negative breast cancer, AR-negative prostate cancer, or other examined cancer cell lines from 
other tissues. ER-dependent accumulation of SHOT-RNAs is not limited to a cell culture system, 
but it also occurs in luminal-type breast cancer patient tissues. SHOT-RNAs are produced from 
aminoacylated mature tRNAs by angiogenin-mediated anticodon cleavage, which is promoted 
by sex hormones and their receptors. Resultant 5′- and 3′-SHOT-RNAs, corresponding to 5′- 
and 3′-tRNA halves, bear a cyclic phosphate (cP) and an amino acid at the 3′-end, respectively. 
By devising “cP-RNA-seq” method that is able to exclusively amplify and sequence cP-
containing RNAs, we identified the complete repertoire of 5′-SHOT-RNAs. Furthermore, 5′-
SHOT-RNA, but not 3′-SHOT-RNA, has significant functional involvement in cell 
proliferation. These results have unveiled a novel tRNA-engaged pathway in tumorigenesis of 
hormone-dependent cancers and implicate SHOT-RNAs as potential candidates for biomarkers 
and therapeutic targets.  
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Significance Statement  
Although transfer RNAs (tRNAs) are best known as adapter molecules essential for 
translation, recent biochemical and computational evidence has led to a previously unexpected 
conceptual consensus that tRNAs are not always end products but can further serve as a source 
of small functional RNAs. Here we report that a novel type of tRNA-derived small RNA, 
termed SHOT-RNAs, are specifically and abundantly expressed in sex hormone-dependent 
breast and prostate cancers. SHOT-RNAs are produced from aminoacylated mature tRNAs by 
angiogenin-mediated cleavage of the anticodon loop, which is promoted by sex hormones and 
their receptors. We identified the complete repertoire of SHOT-RNAs, and also found their 
functional significance in cell proliferation. These results have unveiled a novel tRNA-engaged 
pathway in tumorigenesis.  
 
                
 
 
 
  
   Shozo Honda et al.           4 
 
Introduction 
Transfer RNAs (tRNAs) are universally expressed in all three domains of life, and play 
a central role in protein synthesis as an adapter molecule translating codon triplet sequences 
into amino acids. Mature tRNAs are 70–90-nucleotide (nt) non-coding RNA molecules forming 
a cloverleaf secondary structure that further folds into an L-shaped tertiary structure. The human 
nuclear genome encodes over 500 tRNA genes (1) along with numerous genes of tRNA-
lookalikes resembling nuclear and mitochondrial tRNAs (2). The multiple encoded sites and 
high stability place tRNAs among the most abundant RNA molecules in the cellular 
transcriptome. The abundance of tRNAs varies among different cell and tissue types, and 
altered tRNA abundance and heterogeneity have been implicated in gene expression regulation 
and diseases (2-5). 
Although tRNAs are best known as adapter molecules essential for translation, recent 
experimental and computational evidence has led to a previously unexpected conceptual 
consensus that tRNAs are not always end products but can further serve as a source of small 
functional RNAs. In many organisms, small RNAs are produced from mature tRNAs or their 
precursor transcripts not as random degradation products, but as functional molecules involved 
in many biological processes beyond translation (6-8). According to the proposed nomenclature 
(7), tRNA-derived small RNAs identified to date can be classified into two groups: tRNA 
halves and tRNA-derived fragments (tRFs). tRNA halves are composed of 30–35-nt fragments 
derived from either the 5′- (5′-tRNA half) or 3′-part (3′-tRNA half) of mature tRNAs. Shorter 
than tRNA halves, tRFs range from 13–24 nt in length and are derived from 5′- or 3′-parts of 
mature tRNAs, or 5′-leader or 3′-trailer sequences of precursor tRNAs (pre-tRNAs).  
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The expressions of eukaryotic tRNA halves were shown to be triggered by a variety of 
stress stimuli such as oxidative stress, heat/cold shock, and UV irradiation (9). Therefore, tRNA 
halves are also known as tRNA-derived stress-induced RNAs (tiRNAs) (10), although they are 
also detected under non-stressed conditions (8, 11). In mammalian cells, the angiogenin (ANG), 
a member of the RNase A superfamily, was found to be the enzyme that cleaves the anticodon 
loops of mature tRNAs to produce the tiRNAs (10, 12). Ribonuclease/angiogenin inhibitor 1 
(RNH1), an ANG inhibitor, was shown to be a negative regulatory factor for ANG cleavage 
(10). As other regulatory factors, DNA methyltransferase 2 (Dnmt2) and NOP2/Sun RNA 
methyltransferase 2 (NSun2) modify many tRNAs to generate the 5-methylcytidine (m5C) 
modification, which protects tRNAs from stress-induced cleavage (13, 14). 
Importantly, stress stimuli accumulate the tRNA halves not as non-functional 
degradation by-products but as functional molecules. Stress-induced 5′-tRNA halves promote 
the formation of stress granules (15) and also inhibit global translation by displacing 
translational initiation factor complexes from mRNAs (10, 16). Y-box-binding protein 1 (YB-
1), a multifunctional DNA/RNA-binding protein, associates with 5′-tRNA halves and mediate 
translational inhibition and stress granule formation (16). A unique G-quadruplex structure of 
a 5′-tRNA half is crucial for translation inhibition by binding to YB-1 (17). Supporting 
important roles of tRNA halves in pathogenesis, the accumulation of tRNA halves triggers 
cellular stress responses and apoptosis in NSun2-mutated fibroblasts of patients from 
neurodevelopmental disorders or Nsun2-deficient mice (14).   
Although an increasing number of reports have revealed that tRNA-derived small RNAs 
are involved in various biological processes beyond translation, information regarding their 
expression profiles is fragmented and the molecular basis behind their biogenesis and function 
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remain elusive. Here we report a novel type of tRNA halves that are specifically and abundantly 
expressed in sex hormone-dependent breast and prostate cancers; these are produced by ANG-
cleavage of fully aminoacylated mature tRNAs, which are dependent on the presence of sex 
hormones and their receptors. The complete repertoire of the tRNA halves was determined by 
developing a method that is able to exclusively amplify and sequence tRNA halves. 
Furthermore, the tRNA halves have significant functional involvement in cell proliferation, 
strongly suggesting that our study has unveiled a novel pathway that engages tRNA halves in 
the development and growth of sex hormone-dependent cancers.     
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Results 
tRNA halves are constitutively expressed in BmN4 cells 
In the course of investigating PIWI-interacting RNAs (piRNAs), a germline-specific 
class of small regulatory RNAs (18), we serendipitously detected the expression of tRNA halves 
in BmN4 cells. BmN4 cells are Bombyx mori ovary-derived cultured germ cells that 
endogenously express piRNAs and their bound PIWI proteins; therefore, they present a unique 
model system for piRNA research (19, 20). When we examined the expression of piRNA-a, an 
abundant piRNA expressed in BmN4 cells (20) (DDBJ #DRA002562), a Northern blot probe 
complementary to the piRNA yielded bands of approximately 75 and 35 nucleotides (nt) that 
were much more abundant than the ~28-nt piRNA band (Fig. 1A). Subsequent RACE analyses 
identified the ~35 nt band as a 5′-half of a Bombyx cytoplasmic tRNAAspGUC ranging from the 
5′-end to anticodon 1st nucleotide [nucleotide position (np) 1–34 according to the nucleotide 
numbering system of tRNAs (21)], while piRNA-a was found to be derived from np 1–28 of 
the tRNAAspGUC (Fig. 1B). In addition to the presence of the 5′-tRNAAspGUC half, expression of 
a 3′-half comprising np 35–76 of the tRNAAspGUC was also detected and identified by Northern 
blot and RACE analyses (Fig. 1A, 1B).  
Exploration of the expression of tRNA halves from other randomly-chosen Bombyx 
cytoplasmic tRNAs led to the detection of both the 5′- and 3′-halves derived from tRNAHisGUG 
(Fig. 1C), but failed to show clear signals for tRNA halves from tRNAGlyUCC, tRNAGlyGCC, and 
tRNASerCGA. These results suggested that only specific tRNA species produce abundant tRNA 
halves in BmN4 cells. The 3′-terminal position of the 5′-tRNAHisGUG half was identified to be 
anticodon 1st position (np 34) by RACE (Fig. S2). RACE analysis failed to amplify the 3′-
tRNAHisGUG half, which could be attributed to the presence of a post-transcriptional 
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modification. tRNAHisGUG contains a guanine residue at np 37 which is often modified to 1-
methyl-guanosine (m1G). The m1G modification inhibits reverse-transcription (22), which 
would result in the unsuccessful amplification of the 3′-tRNAHisGUG half by RACE. Interestingly, 
reduced levels of the 5′-tRNAAspGUC expression were observed in BmN4 cells whose cell cycle 
was arrested by double thymidine block (Fig. 1D), implying that the expressions of tRNA 
halves in BmN4 cells are correlated with cell proliferation.  
 
tRNA halves are constitutively expressed in breast cancer cells, but not in non-cancerous 
breast epithelial cells  
The observed potential connection between tRNA halves and cell proliferation prompted 
us to analyze the involvement of tRNA halves in tumorigenesis. Northern blots revealed that 
both 5′- and 3′-tRNA halves derived from human cytoplasmic tRNAAspGUC and tRNAHisGUG 
were abundantly expressed in MCF-7 and BT-474 human breast cancer cells (Fig. 2A), while 
only merely present in HeLa cells and absent in non-cancerous breast epithelial MCF10A cells. 
RACE analysis using BT-474 total RNA showed that the 5′-tRNAAspGUC half and 5′-
tRNAHisGUG half were commonly derived from np 1–34 of respective mature tRNAs, while 
majority of the 3′-tRNAAspGUC halves were derived from np 35–76 (Fig. 2E, S4A, S4B). We 
were not able to amplify the 3′-tRNAHisGUG half, again most likely because of the np 37 m1G 
modification. The examined cells were cultured in medium optimized for the respective cell 
lines under appropriate conditions (e.g., appropriate cell confluence), and only specific cell lines 
showed the expression of tRNA halves. These results imply that the observed expression of 
tRNA halves was a constitutive rather than a stress-induced phenomenon as with tiRNA 
expression.        
   Shozo Honda et al.           9 
 
 
5′-tRNA halves contain a phosphate at the 5′-end and a 2′,3′-cyclic phosphate at the 3′-
end  
To analyze terminal structure of the 5′-tRNA halves, total RNA from BT-474 cells was 
treated with T4 polynucleotide kinase (T4 PNK) or bovine alkaline phosphatase (BAP), and 
then the mobility of the bands of 5′-tRNA halves in Northern blots was examined. T4 PNK 
treatment removes both a phosphate and a 2′,3′-cyclic phosphate from the 3′-end of RNAs, 
while BAP removes a phosphate from both the 5′- and 3′-ends of RNAs. Although BAP 
treatment alone cannot remove a cyclic phosphate from the 3′-end of RNAs, a combination 
treatment of acid and BAP can remove a cyclic phosphate, because the acid converts the cyclic 
phosphate to a phosphate. As shown in Fig. 2B, the bands of the 5′-tRNA halves were shifted 
up by BAP treatment, suggesting the presence of a phosphate in the 5′-tRNA halves. T4 PNK 
treatment similarly shifted the bands up, and further up-shifts were observed by the acid plus 
BAP treatments, indicating the additional presence of a 2′,3′-cyclic phosphate in the 5′-tRNA 
halves. These results indicate that 5′-tRNA halves contain a phosphate at the 5′-end and a 2′,3′-
cyclic phosphate at the 3′-end.  
 
3′-tRNA halves contain a hydroxyl group at the 5′-end and an amino acid at the 3′-end  
To analyze the terminal structures of the 3′-tRNA halves, BT-474 total RNA was 
subjected to deacylation treatment for removal of amino acids from aminoacylated tRNAs, 
followed by sodium periodate oxidation and -elimination, which reacts with 3′-hydroxyl end 
and removes the 3′-terminal nucleotide. As shown in Fig. 2C, -eliminated 3′-tRNA halves 
migrated faster than unreacted RNAs only after the RNAs were subjected to deacylation 
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treatment. In other words, without deacylation treatment, -elimination was unable to react with 
the 3′-end of the 3′-tRNA halves due to the presence of an amino acid. These results strongly 
suggest that 3′-tRNA halves are fully aminoacylated at the 3′-end. For the 5′-end of the 3′-tRNA 
halves, BAP treatment did not influence band positions, while T4 PNK treatment with ATP 
was able to phosphorylate the 5′-end, resulting in up-shifting of the bands (Fig. 2C). These 
results indicate the absence of a phosphate at the 5′-end. Taken together, 3′-tRNA halves contain 
a hydroxyl group at the 5′-end and an amino acid at the 3′-end.     
 
Angiogenin produces the tRNA halves in breast cancer cells  
In mammalian cells, angiogenin (ANG) cleaves the anticodon loops of tRNAs upon 
stress stimuli to produce tiRNAs (10, 12). To determine whether ANG is required for the 
production of tRNA halves in breast cancer, we performed RNAi knockdown of ANG 
expression in BT-474 cells. Both of the two different siRNAs designed to target the ANG gene 
were effective to decrease ANG mRNA levels to around 40% compared with control siRNAs 
(Fig. S6A). Strikingly, transfection with each of the ANG-targeting siRNAs commonly resulted 
in the reduction of tRNA halves from tRNAAspGUC (Fig. S6B) and tRNAHisGUG (Fig. 2D), while 
the levels of corresponding mature tRNAs and control miR-16 did not change. These results 
strongly suggest that the ANG catalyzes the anticodon cleavage of mature tRNAs to produce 
tRNA halves in breast cancer cells (Fig. 2E).  
 
Quantification of SHOT-RNAs by TaqMan qRT-PCR 
Because there was a clear difference in the abundance of tRNA halves between the breast 
cancer cell lines and HeLa (Fig. 2A), we reasoned that the expression profiles of tRNA halves 
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differ among cancer cell lines. In order to perform wide screening of cancer cell lines for the 
tRNA half expressions, there was a need to develop a convenient and accurate method for 
quantification of tRNA halves. Although a PCR-based detection method is more efficient and 
sensitive than Northern blot, standard qRT-PCR amplification of the interior sequences of the 
tRNA halves is not able to distinguish signals among tRNA halves, mature tRNAs, and pre-
tRNAs. To circumvent this issue, we developed a TaqMan qRT-PCR-based method that is able 
to exclusively quantify 5′- or 3′-tRNA halves (Fig. 3A, 3B). Total RNA was first treated with 
T4 PNK and ATP to dephosphorylate the 3′-end of the 5′-tRNA halves, and at the same time to 
phosphorylate the 5′-end of the 3′-tRNA halves. Subsequently, a 3′- or 5′-RNA adapter was 
ligated to the 5′- or 3′-tRNA halves, respectively, followed by quantification of the ligation 
products by TaqMan qRT-PCR. The method successfully amplified and quantified the 5′-
tRNAAspGUC half, 5′-tRNAHisGUG half (Fig. 3A), and 3′-tRNAAspGUC half (Fig. 3B), while no 
signal was detected from attempted amplification of the 3′-tRNAHisGUG half, which was most 
likely because np 37 m1G hindered reverse transcription. Because the TaqMan probes were 
designed to target the boundary of the tRNA halves and RNA adapters, only adapter-ligated 
tRNA halves, but not mature tRNAs and pre-tRNAs, were specifically quantified by this 
method. Indeed, a method without an RNA ligation step failed to produce detectable signals, 
and a method without T4 PNK treatment severely reduced the signals (Fig. 3A, 3B). The 
abundance of tRNA halves was much greater in BT-474 than in HeLa cells, which is consistent 
with the Northern blot results (Fig. 2A); this confirmed the credibility of the method. 
 
Abundant accumulation of tRNA halves in specific breast and prostate cancer cell lines  
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With this novel method, the expression of the three tRNA halves was profiled in 94 cell 
lines from liver, pancreas, stomach, colon, esophagus, oral, lung, breast, and prostate cancers 
as well as in non-cancerous breast epithelial MCF10A cells (Fig. 3C). Each cell line exhibited 
different expression patterns of the tRNA halves, suggesting that production of the tRNA halves 
was specifically regulated. The three cell lines, MCF-7 and BT-474 breast cancer cells and 
LNCaP-FGC prostate cancer cells, showed prominent expression of all three examined tRNA 
halves. None of the other examined cancer cell lines exhibited abundant expression levels of all 
three tRNA halves. As clearly detected in BT-474 and MCF-7 cells (Fig. 2A), both 5′- and 3′-
tRNA halves from tRNAAspGUC and tRNAHisGUG were abundant in LNCaP-FGC cells by 
Northern blots, whereas the other two examined prostate cancer cells, DU145 and PC-3, did 
not show a detectable band for the tRNA halves (Fig. 3D). These results confirm the 
effectiveness of our screening method, and the particularly abundant expression of tRNA halves 
in specific breast and prostate cancer cell lines.      
 
Expression of tRNA halves is dependent on sex hormones and their receptors   
 What are the molecular factors regulating the expression levels of the tRNA halves? 
Notably, the expression levels of mature tRNAAspGUC and tRNAHisGUG, as determined by 
Northern blots (Fig. 2A, 3D), were not particularly high in the MCF-7, BT-474, or LNCaP-
FGC cell lines compared with those in other cancer cell lines. Thus, the abundant expression of 
tRNA halves are not simply because of the enhanced transcription or stability of mature tRNAs.  
One of the main characteristics that distinguish breast and prostate cancers from the other 
cancers screened in Fig. 3C is the crucial involvement of sex hormones and their receptors in 
caner development and progression. High level exposures of estrogen are a major risk factor 
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for breast cancer and approximately 70–75% of breast cancers express estrogen receptor alpha 
(ER), which contributes to estrogen-dependent tumor growth (23). Among four breast cancer 
subtypes, such ER-positive breast cancers are classified into luminal type A or B, while the 
other two subtypes comprises the HER2-positive type, which is ER-negative but expresses 
human epidermal growth factor receptor 2 (HER2), and the triple-negative type, which is 
negative for ER, progesterone receptor, and HER2 (24). Similar to the involvement of estrogen 
and ER in breast cancer, androgens [mainly testosterone and 5-alpha-dihydrotestosterone 
(DHT)] and the androgen receptor (AR) play crucial roles in the tumorigenesis and progression 
of prostate cancer (25). Interestingly, MCF-7 and BT-474 cells, which abundantly express 
tRNA halves, are both ER-positive luminal type breast cancer cell lines (26), while all examined 
ER-negative breast cancer cell lines (HER2-positive type: SK-BR-3 and MDA-MB-453, and 
triple-negative type: HCC1937, HCC1143, BT-20, MDA-MB-231, MDA-MB-157, BT-549, 
and HCC1395) showed low levels of tRNA halves (Fig. 3C). Similarly, among the three 
examined prostate cancer cell lines, AR-positive LNCaP-FGC cells express abundant tRNA 
halves, while AR-negative DU145 and PC-3 cells commonly had low levels of tRNA halves 
(Fig. 3C, 3D). These correlations allowed us to hypothesize that sex hormone sensitivity and 
hormone receptor expression could be a driving force to trigger and regulate the production of 
tRNA halves in breast and prostate cancers.  
To test our hypothesis, we performed RNAi knockdown of ER expression in MCF-7 
and BT-474 breast cancer cells and of AR expression in LNCaP-FGC prostate cancer cells. 
siRNAs targeting ER or AR successfully decreased levels of the target mRNA below 25%, 
while there was no effect on HER2 mRNA (Fig. 4A). Strikingly, in the all three cell lines, ER 
or AR knockdowns commonly reduced the amounts of 5′-tRNAAspGUC half and 5′-tRNAHisGUG 
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half (Fig. 4A). To further confirm our hypothesis, we cultured the three cell lines with hormone-
free medium as an alternative method to create hormone-insensitive states. As shown in Fig. 
4B, the amounts of tRNA halves were decreased in all three cell lines cultured in hormone-free 
medium. Moreover, we added the corresponding sex hormones, estradiol and DHT, to the 
medium culturing MCF-7 and BT-474 breast cancer cells and LNCaP-FGC prostate cancer 
cells, respectively, and observed that the addition of the hormones commonly increased the 
levels of tRNA halves in all three cell lines (Fig. 4C). These results clearly indicate the 
dependency of tRNA half expressions on sex hormones and their receptors. Therefore, we 
termed this novel type of tRNA halves as Sex HOrmone-dependent TRNA-derived RNAs 
(SHOT-RNAs). Hereafter, we will use 5′- or 3′-SHOT-RNAamino acid/anticodon sequence to denote 
SHOT-RNA derived from 5′- or 3′-halves of the tRNA.     
Both ER and AR act as transcription factors to regulate the transcription of many target 
genes upon binding of corresponding hormones (27, 28). However, mRNA expression levels 
of both ANG and RNH1 in LNCaP-FGC cells were not changed when cultured in hormone-
free medium (Fig. S7A), indicating that SHOT-RNA expression is not triggered by the direct 
regulation of ANG and RNH1 transcription by hormone receptors. In addition, we observed 
that RNH1 protein levels were unchanged after culturing in hormone-free medium (Fig. S7B). 
These results suggest that SHOT-RNA generation may not be regulated by RNH1, in contrast 
to the case of tiRNAs where the quantitative changes in RNH1 regulate expression (29).  
 
Development of cP-RNA-seq method to specifically identify cyclic phosphate-containing 
RNA species  
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Next, we aimed to clarify the tRNA species that generate SHOT-RNAs. 5′- and 3′-
SHOT-RNAs contain the 3′-terminal modifications, a 2′,3′-cyclic phosphate and an amino acid 
(Fig. 2B, 2C), which would inhibit the adapter ligation step included in RNA sequencing 
methods. Therefore, RNA sequencing methods without procedures to remove such 3′-
modifications cannot accurately capture SHOT-RNA expressions. To identify a comprehensive 
repertoire of 5′-SHOT-RNAs, we developed a method termed “cP-RNA-seq” that is able to 
exclusively amplify and sequence RNAs containing a 3′-terminal cyclic phosphate (Fig. 5A). 
In the cP-RNA-seq targeting 5′-SHOT-RNAs, 30–50-nt RNAs were first gel-purified from total 
RNA. Then, phosphatase treatment was used to remove a phosphate from both the 5′- and 3′-
ends of the gel-purified RNAs, although the state of cyclic phosphate was not changed. 
Eventually, the RNA pools mainly contained two RNA subgroups, one with both 5′- and 3′-
hydroxyl ends, and a second with 5′-hydroxyl and 3′-cyclic phosphate ends. Subsequent 
periodate treatment cleaved the cis-diol group of the 3′-hydroxyl end of the former group to 
generate 2′,3′-dialdehydes that no longer serve as a substrate for adapter ligation. The latter 
group survived periodate treatment because of the presence of a 3′-cyclic-phosphate. Therefore, 
after removal of cyclic phosphate by kinase treatment, the latter group became the only RNA 
group that bears a 3′-hydroxyl end for 3′-adapter ligation. Subsequent 5′-adapter ligation, RT-
PCR amplification, and next-generation sequencing of the cDNAs thus exclusively identified 
the sequences of 3′-cyclic phosphate-containing RNAs.     
 
Identification of a comprehensive repertoire of SHOT-RNAs  
To capture 5′-SHOT-RNAs, we applied the cP-RNA-seq method to total RNA isolated 
from BT-474 breast cancer cells. The method successfully amplified ~153-bp bands 
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(considering adapters’ lengths, inserted RNAs were estimated to be ~35 nt) (Fig. 5B) whose 
dependency on T4 PNK treatment suggests that as expected the amplified bands were derived 
from cyclic-phosphate-containing RNAs. Consistent with the low levels of 5′-tRNA halves in 
HeLa cells detected by Northern blots (Fig. 2A), this method failed to yield clear bands from 
HeLa total RNA (Fig. 5B). Illumina sequencing of the amplified bands from BT-474 cells 
yielded approximately 33 million reads that aligned to the human genome, of which around 28 
million reads (~85%) were mapped to tRNAs. Among the tRNA mapped reads, we focused the 
RNA species with >10,000 reads that in aggregate accounted for >98.9% of the reads. Of these, 
almost all sequences were unanimously derived from 5′-halves of mature tRNAs with lengths 
of 32–35 nt (Fig. 5C and 5D), which validated the use of the cP-RNA-seq method to capture 
the repertoire of 5′-SHOT-RNAs.   
Only eight cytoplasmic tRNA species were identified to be a source of 5′-SHOT-RNAs 
with >0.1% reads of the 5′-tRNA half sequences identified by cP-RNA-seq (Fig. 5D). 5′-SHOT-
RNALysCUU and 5′-SHOT-RNAHisGUG were particularly enriched, which comprised 60.4% and 
27.5% of the total reads, respectively. As with Northern blot (Fig. 2) and qRT-PCR analyses 
(Fig. 3, 4), 5′-SHOT-RNAAspGUC was also detected by cP-RNA-seq. The majority of the 5′-
SHOT-RNAs were derived from a region that started at np 1 (5′-end) and ended at np 32-34 in 
the anticodon loop of the mature tRNAs (Fig. 5E). The sequence results of 5′-SHOT-
RNAAspGUC and 5′-SHOT-RNAHisGUG were consistent with RACE results (Fig. S4B). The 
identified 3′-terminal position of the 5′-SHOT-RNAs exhibited focal patterns of ANG cleavage 
(Fig. 5F). As the RNase A superfamily has been reported to share substrate preferences for a 
pyrimidine (30, 31), major sites for ANG cleavage within the anticodon loop were located 
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between cytidine and uridine or guanosine and uridine residues, implying that ANG tends to 
cleave the 5′-side of uridines in the anticodon loop.  
 
5′-SHOT-RNAs enhance cell proliferation   
Because the expression of tRNA halves was correlated to cell proliferation in BmN4 cells 
(Fig. 1C), we hypothesized that SHOT-RNAs are not just non-functionally accumulated but 
required as functional molecules for cell proliferation in hormone-dependent cancers. To test 
this hypothesis, we investigated the impact of SHOT-RNA absence on cell proliferation by 
performing siRNA knockdown of SHOT-RNAs. Because SHOT-RNAs share identical 
sequences with mature tRNAs or pre-tRNAs, there was a possibility that siRNAs targeting 
SHOT-RNAs affect mature tRNAs or pre-tRNAs as well as SHOT-RNAs, leading to confusing 
results. However, Lee et al. (32) reported the successful siRNA knockdown of 3′-trailer-derived 
tRNA fragments without affecting pre-tRNA levels. Moreover, Garcia-Silva et al. (33) 
succeeded in selectively staining tRNA fragments without obtaining signals from mature 
tRNAs by avoiding the denaturation step in their modified FISH method. Considering these 
reports and the fact that mature aminoacylated tRNAs form rigid L-shaped tertiary structures 
and tightly bind to EF-Tu in the cytoplasm, we assumed that siRNAs targeting SHOT-RNAs 
could preferably function toward SHOT-RNAs without greatly affecting mature tRNAs. Indeed, 
as described below, all of our siRNA transfections targeting SHOT-RNAs did not affect mature 
tRNA levels but specifically reduced the levels of targeted SHOT-RNAs. 
We first transfected siRNA targeting 5′-SHOT-RNALysCUU, the most abundantly 
sequenced 5′-SHOT-RNA, into LNCaP-FGC prostate cancer cells. Using both qRT-PCR (Fig. 
6A) and Northern blots (Fig. S8), we confirmed that the siRNA transfection specifically 
   Shozo Honda et al.           18 
 
reduced the levels of 5′-SHOT-RNALysCUU. Upon 5′-SHOT-RNALysCUU reduction, strikingly, 
the cell growth rate was decreased compared with control siRNA-transfected cells (Fig. 6B). 
Because the levels of mature tRNA were not changed by siRNA transfection (Fig. 6A, Fig. S8), 
inhibition of cell proliferation appeared to be solely attributable to the change in SHOT-RNA 
levels. 5′-SHOT-RNALysCUU depletion strongly impaired cell proliferation from 3 days after 
siRNA transfection (days 3, 4, and 5). Compared with the day of transfection (day 0), the 
amounts of cells transfected with control siRNA grew by ×3.17 ± 0.717 on day 4, while the 
number of 5′-SHOT-RNALysCUU-silenced cells was almost at the same level (×1.13 ± 0.253) on 
day 4.  
To explore the universality of the effect of SHOT-RNA reduction on cell growth, we 
further performed siRNA knockdown of 5′-SHOT-RNAAspGUC and 5′-SHOT-RNAHisGUG in 
LNCaP-FGC cells. As with the case of 5′-SHOT-RNALysCUU knockdown, respective siRNAs 
commonly reduced the levels of the targeted SHOT-RNA, while non-targeted SHOT-RNA and 
mature tRNA were not affected by the siRNA (Fig. 6C), validating siRNA knockdown as an 
effective method to reduce specific SHOT-RNAs without affecting the corresponding mature 
tRNAs. The depletion of each of 5′-SHOT-RNAAspGUC and 5′-SHOT-RNAHisGUG commonly 
impaired cell growth, resulting in increased cell numbers by only ×1.76 ± 0.320 and ×1.77 ± 
0.145 cell on day 4 compared with day 0, whereas the numbers of control cells increased by 
×2.71 ± 0.373 (Fig. 6D). These results indicate that 5′-SHOT-RNAAspGUC and 5′-SHOT-
RNAHisGUG, as well as 5'-SHOT-RNALysCUU, are required for cell proliferation.  
To examine differences between 5′- and 3′-SHOT-RNA, 3′-SHOT-RNAAspGUC was 
further silenced by siRNA transfection. As shown in Fig. 6E, siRNA specifically reduced the 
levels of targeted 3′-SHOT-RNAAspGUC, but not those of 5′-SHOT-RNAAspGUC or mature 
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tRNAAspGUC, indicating that siRNA silencing of targeted SHOT-RNAs does not influence their 
counterpart SHOT-RNAs or corresponding mature tRNAs. In contrast to the case with 5′-
SHOT-RNAs, 3′-SHOT-RNAAspGUC depletion failed to impair cell growth (Fig. 6F). Taken 
together, these results strongly suggest that SHOT-RNAs are expressed as functional molecules, 
and different species of 5′-SHOT-RNA universally play roles in cell proliferation, while a 3′-
SHOT-RNA bears no impact.  
 
Abundant accumulation of SHOT-RNAs in ER-positive breast cancer patient tissues  
To examine SHOT-RNA expressions in actual patient tissues, total RNA was extracted 
from formalin-fixed paraffin-embedded (FFPE) tissue samples obtained from patients with ER-
positive luminal-type or triple-negative-type (ER-negative) breast cancers and from normal 
breast tissues. Expression of the four 5′-SHOT-RNAs (5′-SHOT-RNALysCUU, 5′-SHOT-
RNAHisGUG, 5′-SHOT-RNAAspGUC, and 5′-SHOT-RNAGluCUC) in the total RNAs was then 
quantified using the TaqMan qRT-PCR (Fig. 7A). Although each tissue sample exhibited 
different expression patterns, the ER-positive patient tissues in particular showed a prominent 
expression level of SHOT-RNAs, while none of the ER-negative patient tissues or normal 
breast tissues exhibited abundant expression levels of SHOT-RNAs. These results confirm the 
effectiveness and sensitivity of our method to quantify SHOT-RNAs in patient tissues, and 
indicate that the phenomenon of hormone-dependent SHOT-RNA accumulation is not limited 
to a cell culture system but it also occurs in actual cancer patient tissues.   
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Discussion 
Here we report the identification of SHOT-RNAs as a novel class of small functional 
RNAs whose expression is dependent on sex hormones and corresponding receptors. Hormone 
dependency was demonstrated by: (1) SHOT-RNAs were prominently and constitutively 
enriched only in ER-positive breast cancer and AR-positive prostate cancer cell lines, whereas 
ER-negative breast cancer, AR-negative prostate cancer, and all examined cancer cell lines 
from other tissues expressed low levels of tRNA halves; (2) SHOT-RNAs were prominently 
enriched only in tissues from ER-positive breast cancer patients but not in those from triple-
negative patients and in normal breast tissues; (3) depletion of sex hormone receptors, ER and 
AR, commonly reduced SHOT-RNA levels; (4) culturing cells in hormone-free medium 
decreased SHOT-RNA levels; and (5) addition of the sex hormones to the cell culture medium 
increased SHOT-RNA levels. We propose the model that the sex hormone-signaling pathways 
activate ANG cleavage of aminoacylated mature tRNAs, and the resultant accumulation of 
SHOT-RNAs contributes to cell proliferation and thereby may promote tumorigenesis and 
tumor growth (Fig. 7B).  
The finding of SHOT-RNAs was motivated by the serendipitous discovery of tRNA 
halves in Bombyx mori ovary-derived BmN4 cells. Because BmN4 cells were cultured in phenol 
red- and FBS-free medium, it appears that the expression of tRNA halves in BmN4 cells is 
independent of hormones and their receptors. In addition, no Bombyx homologue of human 
ANG is found in the silkworm genome (SilkBase: http://silkbase.ab.a.u-tokyo.ac.jp/cgi-
bin/index.cgi). Therefore, the biogenesis mechanisms and their regulation of tRNA halves in 
BmN4 cells are different from those of SHOT-RNAs in cancers.  
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Although SHOT-RNAs and tiRNAs share an identical biogenesis factor (10, 12), they 
are also distinct RNAs. First, SHOT-RNAs are constitutively expressed in specific sex 
hormone-dependent cancer cells, whereas tiRNA expression is triggered by stress stimuli, 
which is a widely conserved phenomenon in various cells. Second, it’s likely that RNH1 is not 
involved in SHOT-RNA production, while the reduced levels of RNH1 contribute to tiRNA 
accumulation (10, 34). Third, tRNA species that generate SHOT-RNAs appear to be different 
than those producing tiRNAs. tiRNAs are widely produced from various tRNAs such as 
tRNAAla, tRNACys, and tRNASer (10, 15, 16, 34), but SHOT-RNAs derived from these tRNAs 
were not identified in our analyses. Fourth, although 5′- and 3′-SHOT-RNAs were expressed 
with similar quantities, tiRNAs have been reported to be asymmetrically expressed with a much 
greater abundance of 5′-tiRNAs compared with their 3′-counterpart (12, 14, 35). Therefore, our 
findings have revealed a novel tRNA-engaged pathway in sex hormone dependent cancers. 
Sex hormones and their receptors play crucial roles in the genesis and progression of 
breast and prostate cancers (23, 25). Sustained exposure to estrogen is well-known promoter of 
breast cancer onset and progression, and at least 70% of breast cancers are classified as ER-
positive luminal type, in which development and growth is dependent on the estrogen-activated 
ER(36). In prostate cancer, androgen plays a crucial role in tumorigenesis by promoting AR-
mediated gene expression regulation (25). The high expression specificity of SHOT-RNAs 
implies their potential usage as a novel biomarker in sex hormone-dependent cancers. Actually, 
the specific and abundant SHOT-RNA accumulation was observed in ER-positive breast cancer 
patient tissues.  Further studies are required to clarify the association of SHOT-RNA expression 
with various prognostic factors. Examining the presence of SHOT-RNAs in exosomes (37) may 
also be interesting for the purpose of developing a biomarker for non-invasive testing.  
   Shozo Honda et al.           22 
 
SHOT-RNAs are generated by ANG cleavage of the anticodon loop of aminoacylated 
cytoplasmic tRNAs, resulting in the accumulation of 5′-SHOT-RNAs containing a phosphate 
at the 5′-end and a 2′,3′-cyclic phosphate at the 3′-end, and of 3′-SHOT-RNAs containing a 5′-
hydroxyl group at the 5′-end and an amino acid at the 3′-end. It is notable that ANG leaves a 
cyclic phosphate, while bovine pancreatic RNase A, the best-studied ribonuclease, leaves a 
phosphate by way of an intermediate cyclic phosphate state (38). The presence of a 3′-terminal 
cyclic phosphate and amino acid in SHOT-RNAs suggest that the SHOT-RNAs will not be 
accurately captured by normal RNA sequencing methods because the 3′-terminal modifications 
hinder the adapter ligation steps. To fully sequence SHOT-RNAs by RNA-seq, total RNA 
should be subjected to deacylation and T4 PNK treatment in advance to remove the 3′-terminal 
cyclic phosphate and amino acid.  
By devising the cP-RNA-seq method, we succeeded in exclusively amplifying and 
identifying the complete 5′-SHOT-RNAs repertoire. Only specific tRNAs become a source for 
SHOT-RNAs. The members of the RNase A superfamily shares a substrate preference for a 
pyrimidine, such that ANG has been reported to cleave the 5′-side of cytidine and uridine (30). 
In the case of SHOT-RNA production, ANG cleavage mainly occurs between 
cytidine/guanosine and uridines. However, because many non-cleaved cytoplasmic tRNAs also 
contain cytidine and uridine in their anticodon loops, the sequence preference of ANG may not 
be the sole reason for the selective production of SHOT-RNAs from specific tRNA sources. It 
is noteworthy that more than 96% of the SHOT-RNA sequence reads were derived from the 
tRNAs with corresponding amino acids that were positively- or negatively-charged, such as 
lysine, histidine, glutamate, and aspartate. Considering that SHOT-RNAs are produced from 
fully-aminoacylated mature tRNAs, the properties of amino acid species may be involved in 
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ANG recognition of tRNAs. Further studies, such as in vitro ANG cleavage analyses of mature 
tRNAs, are required to fully elucidate the regulation of ANG substrate recognition. 
How are the SHOT-RNA expressions promoted by sex hormones and their receptors? In 
breast cancer, estrogen-bound ERs form dimers that activate transcription of target genes by 
directly binding to estrogen response elements (ERE) or by interacting with other transcription 
factors (TFs) (28) (Fig. 7B). In addition, as a non-canonical pathway, extracellular estrogen 
binds to the plasma membrane ERs, which initiates signal cascades via second messengers and 
leads to the activation of other TFs. In prostate cancer, testosterone is converted to DHT by 5α-
reductase, and the DHT-bound ARs form dimers and bind to androgen response elements 
(ARE), inducing the transcription of target genes (Fig. 7B) (27). These transcriptional 
activation systems of target genes by sex hormone-signaling pathways may result in the 
promotion of ANG cleavage, which most likely occurs in the cytoplasm because only mature 
aminoacylated cytoplasmic tRNAs are targeted by ANG. Although our results showed no 
quantitative change in ANG mRNA with changing hormone status, ANG protein levels or 
localization may be affected. Although our results showed no quantitative changes in RNH1 
mRNA and protein levels with changing hormone status, other ANG cofactors may be involved 
with regulation of ANG activity. Alternatively, the altered status of tRNA m5C modification, 
which can be induced by changes in levels of Dnmt2 and NSun2, may regulate SHOT-RNA 
expressions. Further studies are required to determine how the ligand-activated hormone 
receptor pathway is connected to enhanced ANG cleavage for SHOT-RNA productions. On the 
other hand, ER-positive luminal-A is the most heterogenous subtype in breast cancer (39), and 
two of the ER-positive breast cancer cell lines (ZR-75-1 and HCC1500) did not show abundant 
SHOT-RNA expressions. Our results from breast cancer patients also showed that some ER-
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positive samples did not show abundant levels of all the examined SHOT-RNAs, implying that 
the sex hormone pathway is necessary, but not a sole sufficient condition, and other unidentified 
cellular factors may be involved in the expressed repertoire and quantity of SHOT-RNAs. 
Intriguingly, specific knockdowns of three different 5′-SHOT-RNA species, but not a 3′-
SHOT-RNA, commonly resulted in severe impairment of cell proliferation, indicating the 
enhancer roles of SHOT-RNAs in cell proliferation. The important questions remain regarding 
the mechanism behind the enhancement and why only 5′-SHOT-RNA appeared to have a 
functional role in cell proliferation. The asymmetrical results of this study show peculiar 
concordance with those of tiRNA studies reporting that 5′-tiRNAs, but not their 3′-conterparts, 
play active role in stress granule promotion and translational repression (10, 15, 16). 
Investigations and comparisons of subcellular localization patterns and interacting proteins of 
5′- and 3′-SHOT-RNAs may reveal further insights to answer these questions. Because of their 
roles in acceleration of cell proliferation, SHOT-RNAs may play important functions in the 
development and growth of sex hormone-dependent cancers. Although patients with these 
diseases receive endocrine therapy to suppress hormone receptor activity or hormone exposure 
to prevent tumor growth (40, 41), many patients encounter de novo or acquired resistance and 
require more aggressive treatments such as chemotherapy (42, 43). Further studies may lead to 
the use of SHOT-RNAs as potential target candidates for future therapeutic applications in sex 
hormone-dependent breast and prostate cancers. 
 
 
  
   Shozo Honda et al.           25 
 
Materials and Methods 
tRNA sequences 
Sequences of Bombyx and human tRNAs were identified using the tRNAscan-SE 
program (1, 44). As shown in Fig. S1, S3, and S9, the tRNA sequences were sorted by 
mismatches and aligned using DNADynamo software (BlueTractor Software).  
 
Cell culture 
BmN4 cells were cultured as previously described (20). To arrest the cell cycle, double 
thymidine block was performed by incubating BmN4 cells with 2.5 mM thymidine for 16 h, 
then releasing the cells by washing with PBS and incubating for 9 h, and again incubating with 
2.5 mM thymidine for 16 h. The MCF-7 cell line was cultured in MEM medium (Life 
Technologies) containing 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, 1× non-
essential amino acids solution (Life Technologies), and 10 μg/mL insulin (Sigma). HeLa and 
BT-474 cells were cultured in DMEM medium (Life Technologies) containing 10% FBS. 
DU145, PC-3, and LNCaP-FGC cells were cultured in RPMI1640 medium (Life Technologies) 
containing 10% FBS. Human cancer cell lines used for SHOT-RNA screenings (Fig. 3C) were 
obtained from American Type Culture Collection (ATCC), Japanese Collection of Research 
Bioresources (JCRB), Riken Cell Bank (RCB), and Korean Cell Line Bank (KCLB), and 
cultured in appropriate media and conditions. 
 
RACE identification of terminal sequences of tRNA halves 
The sequences of adapters and primers for RACE analysis are shown in Table S1. The 
fraction of 30–50-nt RNAs were gel-purified from the total RNA of BmN4, HeLa, and BT-474 
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cells. For 5′-RACE to analyze the 5′-terminal sequences of the 3′-tRNAAspGUC half, purified 
RNAs were treated with T4 PNK (New England Biolabs) and 100 µM ATP to phosphorylate 
the 5′-end of the 3′-tRNA half. Then, the RNAs were subjected to a ligation reaction with a 5′-
RNA adapter using T4 RNA ligase (T4 Rnl; Fisher Scientific). The ligated RNAs were 
subjected to RT-PCR using the One Step SYBR Ex Taq qRT-PCR Kit (Takara). For 3′-RACE 
to analyze the 3′-terminal sequences of 5′-tRNA halves, RNAs were treated with T4 PNK to 
remove the 3′-terminal cyclic phosphate of the 5′-tRNA halves. Then, the RNAs were subjected 
to a ligation reaction with a 3′-RNA adapter, followed by RT-PCR. The PCR products were 
cloned using the StrataClone PCR cloning kit (Agilent Technologies). 
 
RNA isolation, enzymatic treatment, and β-elimination 
RNA isolation, enzymatic treatment, and β-elimination were performed as previously 
described (20, 45). In brief, total RNA was isolated using TRIsure reagent (Bioline). To 
investigate the terminal structures of SHOT-RNAs, total RNA was treated with BAP (Takara), 
T4 PNK (New England Biolabs, with ATP), or acid (incubation in 10 mM HCl at 4°C for 3 h). 
For deacylation treatment, total RNA was incubated in 20 mM Tris-HCl (pH 9.0) at 37°C for 
40 min. For β-elimination reaction, total RNA was first incubated with 10 mM NaIO4 at 0°C 
for 40 min in the dark. 1 M rhamnose (1/10 volume) was then added to quench unreacted NaIO4 
and incubated at 0°C for 30 min. Subsequently, β-elimination was performed by adding an 
equal volume of 2 M Lys-HCl (pH 8.5) and incubating at 45°C for 90 min.  
 
Northern blot 
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Northern blot analysis was performed as described previously (20). The sequences of 
probes are shown in Table S2. The visualization and quantification were performed with 
storage phosphor autoradiography using Typhoon-9400 and ImageQuant ver. 5.2 (GE 
Healthcare). 
 
RNAi knockdowns of ANG 
For RNAi knockdown of ANG, two siRNAs were designed using the siExplorer 
algorithm (46) and synthesized by Bioland Scientific LLC. The siRNA sequences are shown in 
Table S3. ON-TARGETplus Non-targeting siRNA #2 (#D-001810-02; Dharmacon) was used 
as a negative control. BT-474 cells were transfected with 50 nM of each siRNA using the 
RNAi/MAX kit (Life Technologies). After 72 h of the transfection, the cells were subjected to 
a second transfection reaction with 100 nM of siRNAs, followed by another 72-h incubation 
and then harvested. The efficiency of the RNAi knockdowns was verified by real-time RT-PCR 
quantification of ANG mRNA using SsoFast EvaGreen Supermix (BioRad), which were 
normalized by GAPDH expression levels. The sequences of the primers for real-time RT-PCR 
are shown in Table S4. 
  
Quantification of SHOT-RNAs by TaqMan qRT-PCR 
The sequences of the adapters and primers for SHOT-RNA quantification by TaqMan 
qRT-PCR are shown in Table S5. To dephosphorylate the 3′-end of 5′-SHOT-RNAs, and at the 
same time to phosphorylate the 5′-end of 3′-SHOT-RNAs, 1 µg of total RNA was treated with 
T4 PNK and 100 µM ATP. For quantification of 5′-SHOT-RNAs, 100 ng of the treated RNAs 
were subjected to a ligation reaction (10-µL reaction mixture) with 20 pmol of a 3′-RNA 
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adaptor using T4 Rnl. Subsequently, 1 ng of ligated RNA was subjected to TaqMan qRT-PCR 
(10-µL reaction mixture) using the One Step PrimeScript RT-PCR Kit (Clontech), 400 nM of 
a TaqMan probe targeting the boundary of the SHOT-RNA and 3′-RNA adaptor, and 2 pmol 
each of specific forward and reverse primers. With StepOne Plus Real-time PCR machine 
(Applied Biosystems), the reaction mixture was incubated at 42°C for 5 min and then 95°C for 
10 s, followed by 40 cycles of 95°C for 5 s and 60°C for 34 s. The quantified SHOT-RNA 
levels were normalized to U6 snRNA expression levels quantified by SsoFast EvaGreen 
Supermix (BioRad). For quantification of 3′-SHOT-RNAAspGUC, T4 PNK-treated RNAs were 
subjected to a ligation reaction with a 5′-RNA adapter, followed by TaqMan qRT-PCR.  
 
RNAi knockdown of hormone receptors and cell cultures with hormone-free or hormone-
added medium    
For RNAi knockdown of ESR1 gene that encodes ER, SMARTpool: ON-TARGETplus 
ESR1 siRNA (#L-003401; Dharmacon) was used, while the ON-TARGETplus Non-targeting 
Control Pool (#D-001810; Dharmacon) was used as a negative control. For RNAi knockdown 
of AR, Individual: ON-TARGETplus AR siRNA (#J-003400-06; Dharmacon) was used, and 
ON-TARGETplus Non-targeting siRNA #2 (#D-001810-02; Dharmacon) was used as a 
negative control. MCF-7, BT-474, and LNCaP-FGC cells were transfected with 50 nM of each 
siRNA by a reverse transfection method using the RNAiMAX kit according to the 
manufacture’s instruction and the cells were harvested 72 h after the transfection. The efficiency 
of RNAi knockdown was verified by real-time qRT-PCR using the primers shown in Table S4. 
The expression levels were normalized to GAPDH levels. As an alternative method to create 
hormone-insensitive state, the cells were cultured in phenol red-free medium containing 10% 
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charcoal stripped FBS (CS-FBS; Life Technologies) for 120 h. With respect to hormone 
addition experiments, MCF7 and BT-474 cells were treated for 48 h with 10 nM and 100 nM 
of 17β-Estradiol (Sigma), respectively, and LNCaP-FGC cells were treated for 48 h with 10 
nM of  DHT (Sigma). RNH1 protein levels were examined by a western blot using anti-RNH1 
antibody (Proteintech). -tubulin was examined as an internal control by using anti--tubulin 
(Developmental Studies Hybridoma Bank).      
 
cP-RNA-seq to selectively amplify and sequence 5′-SHOT-RNAs  
As shown in Fig. 5A, 35–50-nt RNAs were gel-purified from BT-474 total RNA. Then, 
the purified RNAs were treated by calf intestinal alkaline phosphatase (CIP; New England 
Biolabs). After phenol-chloroform purification, the RNAs were oxidized by incubation in 10 
mM NaIO4 at 0°C for 40 min in the dark, followed by ethanol precipitation. The RNAs were 
then treated with T4 PNK. After phenol–chloroform purification, directional ligation of 
adapters, cDNA generation, and PCR amplification were performed using the Truseq Small 
RNA Sample Prep kit (Illumina) according to the manufacture’s protocol. The amplified 
cDNAs were sequenced using Illumina hiSeq2000 system at the Functional Genomics Core at 
the University of Pennsylvania. 
 
Bioinformatics analyses of 5′-SHOT-RNAs 
The analyzed 5′-SHOT-RNA sample contains 50,220,564 raw reads and can be found 
publically on GEO # (accession No. will be obtained soon). Prior to mapping we used the 
cutadapt tool (DOI: http://dx.doi.org/10.14806/ej.17.1.200) to remove 3′-adapter sequence: 5′-
TGGAATTCTCGGGTGCCAAGG-3′. We used SHRiMP2 (47) for all read mappings and did 
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not allow for any insertions or deletions when mapping. We used a set of 632 tRNA-reference 
genes comprised of 610 nuclear tRNAs from the GRCh37 (hg19) human genome assembly 
(listed in gtRNAdb (1)) and 22 known mitochondrial tRNAs from tRNAdb (48). The 610 
entries from gtRNAdb include 508 true tRNAs and 102 psuedo-tRNAs. We purposely excluded 
selenocysteine tRNA, tRNAs with undetermined anticodon identity, and tRNAs mapping to 
contigs that are not part of the major chromosome assembly. To help validate the “cP-RNA-
seq” method by confirming that most of the reads landed on tRNAs and to account for the 
repetitive nature of tRNA sequences, we mapped the reads to the full-genome allowing a 4% 
mismatch rate and allowing nonunique mappings. Approximately 33 million reads mapped of 
which ~28 million (~85%) intersected with at least 1 of the 632 tRNA-reference genes.  
 
RNAi knockdown of SHOT-RNAs 
siRNA targeting each SHOT-RNA was designed using siExplorer (46) and synthesized 
by Bioland Scientific LLC. The siRNA sequences are shown in Table S3. The ON-
TARGETplus Non-targeting siRNA #2 (#D-001810-02; Dharmacon) was used as a negative 
control. The LNCaP-FGC cells were transfected with each siRNA (10 nM for 5′-SHOT-
RNALysCUU and 3′-SHOT-RNAAspGUC, 20 nM for 5′-SHOT-RNAAspGUC and 5′-SHOT-
RNAHisGUG) using the reverse transfection method with the RNAiMAX kit according to the 
manufacture’s protocol. The efficiency of RNAi knockdown was verified by quantification of 
SHOT-RNAs 72 h after transfection. The expression levels were normalized to U6 snRNA 
levels. Mature tRNALysCUU and tRNAAspGUC were quantified by four-leaf clover qRT-PCR (FL-
PCR (49). The sequences of adapters and primers for FL-PCR are shown in Table S6. Briefly, 
total RNA was subjected to deacylation treatment, followed by ligation reaction with a 
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DNA/RNA-hybrid stem-loop adapter using T4 RNA ligase 2 (New England Biolabs) that 
specifically ligates the adapter to mature tRNA. The ligation products were specifically 
amplified and quantified by TaqMan qRT-PCR.  
 
Cell proliferation assay 
LNCaP-FGC cells were transfected with the SHOT-RNA-targeted siRNAs and plated in 
a 96-well cell culture plate. Cell proliferation and viability were determined with AlamarBlue 
Cell Viability Reagent (Life Technologies). At 24, 48, 72, 96, and 120 h after transfection, 
AlamarBlue reagent was added to the medium and the cells were incubated for another 6 h. 
Absorbance was measured at 570 and 600 nm and relative cell abundance was calculated using 
the manufacturer’s instruction. 
 
SHOT-RNA quantification using breast cancer patient FFPE samples 
Total RNA was extracted from 1–3 10 m- thick FFPE sections using the RecoverAll 
Total Nucleic Acid Isolation Kit (Life technologies) according to the manufacturer’s protocol. 
A total RNA amount of 100 ng was treated with T4 PNK and 100 µM ATP, following which 
50 ng of the treated RNAs were subjected to a ligation reaction (10-µL reaction mixture) with 
20 pmol of a 3′-RNA adaptor using T4 Rnl. Subsequently, 500 pg of ligated RNA was subjected 
to TaqMan qRT-PCR as described above for SHOT-RNA detection using cell lines. 5S rRNA 
expression levels were quantified by SsoFast EvaGreen Supermix (BioRad) and used for 
normalization.  
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Figure Legends 
Figure 1. tRNA halves were highly expressed in BmN4 cells 
(A) BmN4 total RNA was subjected to Northern blot using a probe targeting the 5′- (5′-probe) 
or 3′-part (3′-probe) of Bombyx cytoplasmic tRNAAspGUC. Detected mature tRNA, piRNA-a, 
and 5′- and 3′-tRNA halves are indicated by arrows. 
(B) The cloverleaf secondary structure of Bombyx cytoplasmic tRNAAspGUC-V1 (Fig. S1A) is 
shown. Nucleotide positions (np) are indicated according to the nucleotide numbering system 
of tRNAs (21). Sequences of the tRNAAspGUC halves were identified by RACE analyses. All 3′-
RACE products (10 out of 10) cloned from 5′-tRNA halves had their 3′-terminal positions at 
np 34, whereas all 5′-RACE products (12 out of 12) cloned from 3′-tRNA halves had their 5′-
terminal positions at np 35. piRNA-a was found to be derived from np 1–28 of tRNAAspGUC.  
(C) BmN4 total RNA was subjected to Northern blot targeting Bombyx cytoplasmic 
tRNAHisGUG.  
(D) BmN4 cells were subjected to thymidine block treatment and total RNA from the cells was 
subjected to Northern blot using a 5′-probe for tRNAAspGUC.  
 
Figure 2. tRNA halves were abundantly present in human breast cancer cells 
(A) Total RNA from the indicated cells was subjected to Northern blot using a 5′- or 3′-probe 
targeting human cytoplasmic tRNAAspGUC and tRNAHisGUG. Detected mature tRNAs and tRNA 
halves are indicated by arrows.  
(B) Terminal structure of 5′-tRNA halves in BT-474 cells were analyzed enzymatically. Total 
RNA was treated with T4 PNK, BAP, or acid followed by BAP treatment (HCl+BAP). NT 
designates non-treated sample used as a negative control. The treated total RNA was subjected 
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to Northern blots targeting the 5′-tRNAAspGUC half, 5′-tRNAHisGUG half, and microRNA-16 
(miR-16). miR-16 was investigated as a control RNA containing 5′-phosphate and 3′-hydroxyl 
terminal structures, which are thought to react with BAP but not with T4 PNK. Indeed, BAP 
treatment up-shifted the miR-16 band, while T4 PNK did not.  
(C) To analyze the terminal structure of 3′-tRNA halves, BT-474 total RNA was subjected to 
deacylation treatment, sodium periodate oxidation followed by -elimination, BAP treatment, 
or T4 PNK treatment. The 3′-tRNAAspGUC half, 3′-tRNAHisGUG half, and miR-16 in the treated 
total RNA were analyzed by Northern blots. Since miR-16 contains 5′-phosphate and 3′-
hydroxyl ends, -elimination shortened miR-16 regardless of deacylation treatment. BAP 
treatment, but not T4 PNK treatment, up-shifted the miR-16 band by removing its 5′-phosphate. 
The PAGE for 3′-AspGUC detection in the deacylation minus lane leaned (entire picture of the 
PAGE is shown in Fig. S5), and a dotted line indicates the extent of the leaning.    
(D) BT-474 cells were transfected with control siRNA or the two different siRNAs targeting 
ANG. Upper: total RNA was extracted and subjected to Northern blots for detection of mature 
tRNAHisGUG, 5′-tRNAHisGUG, and miR-16 (negative control). Lower: the Northern blot bands 
were quantified and shown as relative abundance; amounts in control cells were set as 1.    
(E) Schematic description of the production of tRNA halves in breast cancer cells.  
 
Figure 3. Screening of cancer cell lines for the expressions of tRNA halves 
(A) Left: a schematic representation of 5′-tRNA half quantification. Right: the 5′-tRNAAspGUC 
half and 5′-tRNAHisGUG half in BT-474 and HeLa total RNA were quantified using a method 
with or without T4 PNK or T4 Rnl treatment. 
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(B) Left: a schematic representation of 3′-tRNA half quantification. Right: the 3′-tRNAAspGUC 
half was quantified by using the method described for BT-474 and HeLa total RNA. 
(C) Expression levels of the 5′-tRNAAspGUC half, 5′-tRNAHisGUG, and 3′-tRNAAspGUC half in the 
indicated cancer cell lines were examined. Expression levels in BT20 cells were set as 1, and 
fold-changes are indicated. Averages of three independent experiments with SD values are 
shown.  
(D) Total RNA from the indicated prostate cancer cell lines were subjected to Northern blot for 
detection of tRNA halves derived from tRNAAspGUC and tRNAHisGUG. Detected mature tRNAs 
and tRNA halves are indicated by arrows.  
 
Figure 4. Dependency of tRNA halves expression on sex hormones and their receptors   
(A) MCF-7 and BT-474 cells were transfected with control siRNA or siRNA targeting the ESR1 
gene encoding ER, while LNCaP-FGC cells were treated with control siRNA or siRNA 
targeting the AR. After 72 h of transfection, expression levels of ESR1, AR, and HER2 
(negative control) mRNAs and of the 5′-tRNAAspGUC half and 5′-tRNAHisGUG half were 
quantified. Expression levels of control siRNA-treated cells were set as 1. Each data set 
represents the average of three independent experiments with bars showing the SD.   
(B) The indicated cells were cultured in medium containing normal FBS or hormone-free CS-
FBS. After culturing for 120 h, the 5′-tRNAAspGUC half and 5′-tRNAHisGUG half were quantified. 
(C) The indicated cells were cultured in medium containing 17-β estradiol (E2) or DHT. After 
culturing for 48 h, the 5′-tRNAAspGUC half and 5′-tRNAHisGUG half were quantified.  
 
Figure 5. Identification of 5′-SHOT-RNAs by cP-RNA-seq   
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(A) A flow chart of the cP-RNA-seq procedure.  
(B) Total RNA extracted from BT-474 and HeLa cells was applied to cP-RNA-seq method. 
The method amplified ~153-bp cDNA products (5′-adapter, 55 bp; 3′-adapter, 63 bp; and 
therefore inserted sequences, ~35 bp) from BT-474 cells.      
(C) Read-length distribution of the tRNA-mapped reads.   
(D) Pie charts showing the percentage of reads derived from respective cytoplasmic tRNA 
species.    
(E) Pie charts showing the mature tRNA regions from which the sequenced 5′-SHOT-RNAs 
were derived.   
(F) Based on the 3′-terminal sequences of 5′-SHOT-RNAs, the ANG cleavage sites in the 
anticodon loops were predicted. Arrow heads, thick arrows, thin arrows, and short strokes 
designates the 3′-terminal positions of each 5′-SHOT-RNA occupying 75–100%, 50–75%, 25–
50%, and 10–25% of the reads, respectively.   
 
Figure 6. Knockdown of 5′-SHOT-RNA inhibited cell proliferation   
(A), (C), and (E) LNCaP-FGC cells were transfected with control siRNA or siRNA targeting 
the indicated SHOT-RNAs. After 72 h of transfection, expression levels of SHOT-RNAs were 
quantified by the method described in Fig. 3. Mature tRNA levels were quantified by FL-PCR 
(49). Expression levels from control siRNA-treated cells were set as 1. Each data set represents 
the average of three independent experiments with bars showing the SD. 
(B), (D), and (F) The relative abundance of LNCaP-FGC cells at 1, 2, 3, 4, and 5 days after 
transfection of the indicated siRNAs were examined using AlamarBlue assay. Cell abundance 
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on the day of transfection was set at 1. Each data set represents the average of three independent 
experiments with bars showing the SD. 
 
Figure 7. SHOT-RNA expressions in breast cancer patient tissues  
(A) Total RNA was extracted from FFPE tissues obtained from 5 ER-positive breast cancer 
patients (ER+), 5 triple-negative breast cancer patients (TNBC), and 5 normal breast tissues 
(Normal), and subjected to TaqMan qRT-PCR quantification (shown in Fig. 3) of the indicated 
SHOT-RNAs. Expression levels of sample 1 (TNBC) were set as 1. Each data set represents 
the average of three independent experiments with bars showing the SD.   
(B) A proposed model for SHOT-RNA involvement in sex hormone-dependent breast and 
prostate cancers  
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Supplementary Figure Legends 
Figure S1. Variant sequences of Bombyx cytoplasmic tRNAAspGUC (A) and tRNAHisGUG (B) 
According to RACE analyses, tRNA halves from tRNAAspGUC in BmN4 cells were derived from 
variant 1 (shown in square).  
 
Figure S2. RACE identification of 5′-tRNAHisGUG half sequences in Bombyx BmN4 cells  
The cloverleaf secondary structure of the Bombyx cytoplasmic tRNAHisGUG is shown. Sequences 
of the tRNA halves derived from the tRNAHisGUG were identified by RACE analysis. All 3′-
RACE products (10 out of 10) cloned from 5′-tRNA halves had 3′-terminal positions at np 34. 
5′-RACE for 3′-tRNA half failed to amplify detectable bands, most likely because the m1G 
modification at np 37 inhibited reverse transcription.  
 
Figure S3. Variant sequences of human cytoplasmic tRNAAspGUC (A) and tRNAHisGUG (B) 
 
Figure S4. RACE identification of the sequences of tRNA halves derived from tRNAAspGUC 
and tRNAHisGUG in human BT-474 cells  
(A) RNAs extracted from HeLa and BT-474 cells were subjected to RACE analyses for 
sequence identification of tRNA halves derived from human cytoplasmic tRNAAspGUC and 
tRNAHisGUG. RACE reactions from BT-474 RNA, but not those from HeLa RNA, yielded clear 
amplified bands for the 5′- and 3′-tRNAAspGUC halves and 5′-tRNAHisGUG half, which is 
consistent with the abundant expression of the tRNA halves in BT-474 cells and the barely 
detectable expression in HeLa cells (Fig. 2A). RACE for 3′-tRNAHisGUG half failed to amplify 
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detectable bands, most likely because the m1G modification at np 37 inhibited reverse 
transcription.  
(B) The cloverleaf secondary structures of the human cytoplasmic tRNAAspGUC-V1 and 
tRNAHisGUG-V1 are shown. All 3′-RACE products cloned from the 5′-tRNA halves (15 out of 
15 from 5′-tRNAAspGUC, and 13 out of 13 from 5′-tRNAHisGUG) had 3′-terminal positions at np 
34. The majority of the 5′-RACE products (9 out of 10) cloned from 3′-tRNAAspGUC halves had 
5′-terminal positions at np 35, while np 36 was the 5′-terminal position in one clone.  
 
Figure S5. Entire gel picture whose designated region (red square) was shown in Fig. 2C  
 
Figure S6. Reduction of tRNA halves upon siRNA knockdown of ANG  
(A) BT-474 cells were transfected with control (Ctrl) siRNA or the two different siRNAs 
targeting the ANG gene. Total RNA was extracted from the cells after 72 h of transfection. 
ANG mRNA was quantified by real-time qRT-PCR. Expression levels from control siRNA-
treated cells were set as 1 and relative expression levels of ANG mRNAs are indicated. Each 
data set represents the average of three independent experiments with bars showing the SD.   
(B) Mature tRNAAspGUC, 5′-tRNAAspGUC, and miR-16 (negative control) in total RNA extracted 
from ANG siRNA-treated cells were detected by Northern blot. The Northern blot bands were 
quantified and shown as relative abundance; amounts in control cells were set as 1.    
 
Figure S7. Alteration of hormone status did not influence ANG and RNH1 expression 
levels   
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(A) LNCaP-FGC cells were cultured in medium containing normal FBS or hormone-free CS-
FBS. After culturing for 120 h, total RNA was extracted and ANG and RNH1 mRNA levels 
were quantified by real-time qRT-PCR. Expression levels in the cells cultured with normal FBS 
were set as 1, and average of three independent experiments with SD values are shown.  
(B) By Western blots, RNH1 protein levels were examined in LNCaP-FGC cells cultured with 
FBS or CS-FBS for 120 h. The levels of -tubulin were also examined as a control.  
 
Figure S8. siRNA targeting SHOT-RNA reduced the levels of the SHOT-RNA without 
affecting mature tRNA levels   
(A) LNCaP-FGC cells were transfected with control siRNA or siRNA targeting 5′-SHOT-
RNALysCUU. After 72 h of transfection, total RNA was extracted and subjected to Northern blot 
to detect 5′-SHOT-RNALysCUU and mature tRNALysCUU. The asterisk indicates the detection of 
one of the strands of the transfected siRNA.   
(B) The Northern blot bands were quantified and shown as relative abundance; amounts in 
control cells were set as 1.  
 
Figure S9. Variant sequences of human cytoplasmic tRNALysCUU (A), tRNAGluCUC (B), 
tRNAValAAC (C), tRNAValCAC (D), tRNAGlnCUG (E), tRNALysUUU (F), and tRNAGlyGCC (G) 
Among 5′-SHOT-RNALysCUU reads shown in Fig 5D, 24.4%, 0.25%, 0.2%, and 75.2% were 
derived from tRNALysCUU-V1, V2, -V1/V2, and -V3/V4, respectively. Among 5′-SHOT-
RNAGluCUC reads, 84.5% and 15.5% were derived from tRNAGluCUC-V1/V2, and -V1/V2/V5. 
Among 5′-SHOT-RNALysUUU reads, 49.8% and 50.2% were derived from tRNALysUUU-V1/V2, 
and -V1/V2/V3. All 5′-SHOT-RNAValAAC/CAC reads were derived from tRNAValAAC-V1/V2 or 
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tRNAValCAC-V1/V2/V3. All reads of 5′-SHOT-RNAHisGUG, 5′-SHOT-RNAGlnCUG, 5′-SHOT-
RNAAspGUC, and 5′-SHOT-RNAGlyGCC were derived from tRNAHisGUG-V1, tRNAGlnCUG-
V1/V2/V3, tRNAAspGUC-V1, and tRNAGlyGCC-V1, respectively.  
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Table S1.  Sequences of adapters and primers for RACE analysis 
RACE  Adapter/primer Sequence (5′–3′) 
5′-RACE  
5′-RNA adapter GUUCAGAGUUCUACAGUCCGACGAUC 
3′-tRNAAspGUC half-forward primer GTTCAGAGTTCTACAGTCCGACGATC 
3′-tRNAAspGUC half-reverse primer TGGCTCCCCGTCGGGGAATC 
3′-RACE 
3′-RNA adapter 5phos/UGGAAUUCUCGGGUGCCAAGG/3ddC 
5′-tRNAAspGUC half-forward primer GCGGTCCTCGTTAGTATAGT 
5′-tRNAHisGUG half-forward primer GCTCGCCGTGATCGTATAGT 
Common reverse primer GCCTTGGCACCCGAGAATTCCA 
 
Table S2.  Sequences of probes for Northern blot analysis 
Target Sequence (5′–3′) 
Bombyx 5′-tRNAAspGUC half GGGATACTGACCACTATACTACCGAAGA 
Bombyx 3′-tRNAAspGUC half CGGCGGGGAATCGAACCCCGGTCTCCC 
Bombyx 5′-tRNAHisGUG half GGGTCCTAACCACTAGACGA 
Bombyx 3′-tRNAHisGUG half AAATTCGAACCTGGGTTACT 
human 5′-tRNAAspGUC half GGGATACTCACCACTATACTAACGAGGA 
human 3′-tRNAAspGUC half GTCGGGGAATCGAACCCCGGTCTCC 
human 5′-tRNAHisGUG half CAGAGTACTAACCACTATACGATCACGGC 
human 3′-tRNAHisGUG half GCCGTGACTCGGATTCGAACCGAGGTT 
human 5′-tRNALysCUU half GTCTCATGCTCTACCGACT 
All synthetic probes and primes used in this study were synthesized by Integrated DNA 
Technologies. Locked Nucleic Acid (LNA)-modified probes were used for the detection of 
Bombyx 5′- and 3′-tRNAHisGUG halves (underlined letters designate LNA).  
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Table S3.  Sequences of the sense strand of siRNAs with 3′-overhangs, which were designed using 
siExplorer (46) 
Target Sequence (5′–3′) 
ANG-1 AAACCUAAGAAUAAGCAAGUCAU 
ANG-2 CCUAAGAAUAAGCAAGUCUAU 
5′-SHOT-RNALysCUU AGCUCAGUCGGUAGAGCAUUU 
5′-SHOT-RNAAspGUC GUUAGUAUAGUGGUGAGUAUU 
5′-SHOT-RNAHisGUG UCGUAUAGUGGUUAGUACUUU 
3′-SHOT-RNAAspGUC GCGGGAGACCGGGGUUCGAUU 
 
Table S4.  Sequences of primers for real-time qRT-PCR 
Primer Sequence (5′–3′) 
ANG-forward primer AGAAGCGGGTGAGAAACAAAAC 
ANG-reverse primer AGTGCTGGGTCAGGAAGTGTG 
GAPDH-forward primer GTCTTCACCACCATGGAGAAGG 
GAPDH-reverse primer ATGATCTTGAGGCTGTTGTCAT 
U6 snRNA-forward primer TCGCTTCGGCAGCACATATAC 
U6 snRNA-reverse primer CGAATTTGCGTGTCATCCTTG 
ESR1-forward primer CGGCTCCGTAAATGCTACGA 
ESR1-reverse primer TGGCAGCTCTCATGTCTCCA 
AR-forward primer AGCTCACCAAGCTCCTGGACTC 
AR-reverse primer TTGGGCACTTGCACAGAGATG 
HER2-forward primer CAGAGCAGCTCCAAGTGTTTG 
HER2-reverse primer GGTTCTGGAAGACGCTGAGG 
RNH1-forward primer AACAACAGGCTGGAGGATGC 
RNH1-reverse primer TCACGCAGGCTGTGGTTG 
5S rRNA-forward primer TACGGCCATACCACCCTGAAC 
5S rRNA-reverse primer CGGTCTCCCATCCAAGTACTAACC 
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Table S5.  Sequences of adapters and primers for SHOT-RNA quantification by 
TaqMan qRT-PCR  
Target  Adapter/primer Sequence (5′–3′) 
5′-tRNAAspGUC 
3′-RNA adaptor 
/5Phos/GAACACUGCGUUUGCUGGCUUUGAGAGU
UCUACAGUCCGACGAUC/3ddC/ 
TaqMan probe 
/56FAM/TATCCCCGC/ZEN/CTGGAACACTGCGTTT
/3IABkFQ/ 
Forward primer GCGGTCCTCGTTAGTATAGT 
Reverse primer GCCTTGGCACCCGAGAATTCCA 
5′-tRNAHisGUG 
3′-RNA adaptor 
/5Phos/GAACACUGCGUUUGCUGGCUUUGAGAGU
UCUACAGUCCGACGAUC/3ddC/ 
TaqMan probe 
/5HEX/TAGTACTCT/ZEN/GCGTTGGAACACTGCG
TTTGC/3IABkFQ/ 
Forward primer GCTCGCCGTGATCGTATAGT 
Reverse primer GCCTTGGCACCCGAGAATTCCA 
5′-tRNALysCUU 
3′-RNA adaptor 
/5Phos/GAACACUGCGUUUGCUGGCUUUGAGAGU
UCUACAGUCCGACGAUC/3ddC/ 
TaqMan probe 
/56FAM/AGAGCATGG/ZEN/GACTCGAACACTG/3I
ABkFQ/ 
Forward primer GCCCGGCTAGCTCAG 
 Reverse primer GCCTTGGCACCCGAGAATTCCA 
3′-tRNAAspGUC 
 
5′-RNA adaptor 
GAACACUGCGUUUGCUGGCUUUGAUGAAAGUU
CAGAGUUCUACAGUCCGACGAUC 
TaqMan probe 
/56FAM/CAGTCCGAC/ZEN/GATCTCACGCGGGAG
AC/3IABkFQ/ 
Forward primer GCGGTCCTCGTTAGTATAGT 
Reverse primer GCTCGCCGTGATCGTATAGT 
 3′-RNA adaptor 
/5Phos/GAACACUGCGUUUGCUGGCUUUGAGAGU
UCUACAGUCCGACGAUC/3ddC/ 
5′-tRNAGluCUC TaqMan probe 
/56FAM/CGCTCGAAC/ZEN/ACTGCGTTTG/3IABkF
Q/ 
 Forward primer TCCCTGGTGGTCTAGTGG 
 Reverse primer GCCTTGGCACCCGAGAATTCCA 
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A, G, C, and T designate DNA, whereas rG and rC designate RNA.  
Table S6.  Sequences of adapters and primers for mature tRNA quantifications by FL-PCR 
Adapter/primer Sequence (5′–3′) 
Stem-loop adapter /5Phos/TCGTAGGGTCCGAGGTATTCACGATGrGrC 
tRNALysCUU-forward primer GTTCGAGCCCCACGTT 
tRNALysCUU-reverse primer ACTGAGCTAGCCGGGC 
tRNAAspGUC-forward primer CGGGAGACCGGGGTTCGATT 
tRNAAspGUC-reverse primer CGGGGATACTCACCACTATACTAACGAGGA 
